Key facts
- Notable investors include HopStone Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Aptabridge Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Aptabridge Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aptabridge Therapeutics
Developer of a drug design platform designed to leverage DNA nanoparticles for immunotherapy. The company's platform applies modular nanoparticle structures to assemble multi-specific therapeutic constructs, incorporates computational analysis for biomarker identification and molecular design, supports interchangeable targeting components and scalable manufacturing processes, and integrates research and production workflows, enabling biotechnology and pharmaceutical markets to develop adaptable immunotherapies with improved targeting precision and production efficiency.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2021
- Employees
- 5
- Website
- aptabridge.com/
- Ownership
- Privately Held (backing)
Aptabridge Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aptabridge Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aptabridge Therapeutics in its N-PORT filings yet. We sweep new filings monthly.